Recosine

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Recosine

Property Description
Active Ingredient Glucosamine (typically sulfate or hydrochloride)
Form Oral Solid (Capsules, Tablets) or Oral Soluble Powder
Pharmacological Class Connective Tissue Metabolism Regulator
General Purpose Joint Health Management and Structural Support
Origin Endogenous substance, administered exogenously

Recosine: Classification and Active Component

Recosine is the trade name for a preparation containing the active component Glucosamine, an amino sugar structurally classified as a Connective Tissue Metabolism Regulator. Glucosamine, commonly sourced as the sulfate or hydrochloride salt, is an endogenous substance naturally found in the body, primarily in the cartilage matrix, with Recosine providing an exogenous source to the system. This compound is a key precursor for the synthesis of glycosaminoglycans and proteoglycans, essential for cartilage structure. Glucosamine is a fundamental structural component of connective tissue.

What Type of Preparation Is Glucosamine?

Recosine is typically supplied for oral administration in oral dosage forms, such as capsules, tablets, or powders for solution. The regulatory classification of these preparations is variable: certain formulations are registered as medicinal products or Symptomatic Slow-Acting Drugs for Osteoarthritis (SYSADOA) in Europe, while they are often treated as Dietary Supplements in the United States. Glucosamine is commonly used in managing discomfort associated with mechanical joint issues.

The General Purpose of Recosine

  • The general purpose of Recosine is to assist in the long-term maintenance of cartilage matrix integrity and support overall joint function. By providing the necessary structural building block, Glucosamine supports the body's mechanisms for structural upkeep. This action aids in sustaining the structural framework of connective tissues and may thereby contribute to the reduction of discomfort related to mechanical wear and tear. The preparation is used as a component of a comprehensive strategy aimed at supporting joint stability and promoting sustained comfort.

What side effects are possible with Recosine?

Possible Side Effects and Safety Information

The officially documented safety profile of Recosine (Glucosamine) outlines potential adverse reactions categorized by frequency and the body system affected, based on regulatory standards such as those from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

Commonly Documented Adverse Reactions

The reactions most frequently listed in regulatory documents (classified as common, or affecting up to 1 in 10 individuals) are typically related to the Gastrointestinal System and Nervous System. These include gastrointestinal disturbances such as nausea, abdominal pain, dyspepsia, constipation, and diarrhea. General non-specific effects like headache and fatigue are also classified as common.

Uncommon and Serious Adverse Reactions

Less frequently reported reactions (uncommon) involve the skin, presenting as skin rash, pruritus (itching), and erythema (redness). The official safety documentation notes the potential for severe hypersensitivity reactions, which, while rare, are considered clinically significant and are a focus of regulatory warnings.

Safety Considerations for Specific Populations

Official labeling defines specific safety considerations for certain patient groups. Individuals with Diabetes Mellitus should be aware that Glucosamine may impact glucose tolerance, and monitoring of blood glucose levels is a commonly advised safety measure. Furthermore, an important safety constraint is documented for patients using coumarin-based anticoagulants (e.g., Warfarin), due to the potential for Glucosamine to potentiate the anticoagulant effect, requiring close monitoring of coagulation parameters. The product is also contraindicated in individuals with known shellfish allergies, if the Glucosamine is sourced from crustaceans.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory guidance emphasizes that in the event of suspected overdose of Recosine (Glucosamine), individuals must seek immediate medical attention or contact emergency services, even if symptoms are not yet apparent. This action is mandated because, as explicitly stated in authoritative prescribing information, no specific antidote is known for Glucosamine overexposure. The management is therefore strictly symptomatic and supportive.

Regulators generally characterize Glucosamine as having low acute toxicity. Documented clinical manifestations of overdose are typically non-specific and are centered on the gastrointestinal and nervous systems. These documented presentations include nausea, vomiting, diarrhoea, constipation, headache, and dizziness.

Classification Regulatory Statement
Antidote Status No specific antidote is known.
Required Action Seek immediate medical attention.
Treatment Symptomatic and supportive measures.

In cases of massive acute ingestion, the official profile indicates that hospital monitoring may be required, including potential observation for several days to assess for delayed effects. Patients with underlying conditions like impaired glucose tolerance may require closer monitoring during an overdose assessment.

Therapeutic Uses of Recosine

What Recosine Treats: Main Uses and Benefits

Recosine (Glucosamine) is commonly used to help manage chronic joint conditions where symptoms are linked to structural changes, playing a role in the long-term management of discomfort and physical function. The preparation is used in supporting the management of symptoms associated with mild to moderate osteoarthritis of the knee.


This preparation is generally applied in addressing degenerative joint disease and chronic joint wear and tear, and may assist with managing functional impairment such as joint stiffness, localized pain, and restricted range of motion. Its role is in supporting comfort and maintaining functional stability during periods of heightened discomfort.

“Recosine is applied when symptoms create noticeable physiological strain, assisting with maintaining functional stability.”

Quick Fact: Support for Stiffness Symptoms Recosine is considered relevant for easing the stiffness and restriction of movement that accompany joint wear, which contributes to easing the overall symptom load during periods of heightened discomfort.


The application is centered on providing supportive relief for symptoms related to the degenerative changes, which may help patients cope more steadily with symptom fluctuations.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Recosine

The eligibility profile for Recosine (Glucosamine) is strictly defined by regulatory documents, establishing who is permitted to use the medicine and who is formally excluded (contraindicated).


Populations with Established Use

Recosine is approved for use only in adults who are 18 years and older.

Absolute Prohibitions (Contraindications)

The medicine is formally contraindicated and must not be used by patients with a known shellfish allergy or hypersensitivity to Glucosamine or any excipient in the formulation. Use is also contraindicated in patients with certain hereditary sugar intolerances (such as galactose, fructose, or lactose intolerance) when specific excipients are present in the product form.


Populations Requiring Restriction or Caution

  • Children and Adolescents (Under 18): Use should not be used as safety and efficacy have not been established in this age group.
  • Pregnancy and Breastfeeding: Use should not be used during pregnancy and is not recommended while breastfeeding, due to insufficient safety data.
  • Comorbidities: Caution and close medical supervision are required for patients with impaired glucose tolerance (diabetes), a history of asthma, and those with severe hepatic or renal insufficiency.

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information for Recosine (Glucosamine)

Interaction scope

Element Description
Medicinal product categories with documented interactions: Oral Vitamin K Antagonists (Coumarinic Anticoagulants); Tetracycline-class antibiotics; Hypoglycaemic Agents.
Specific interacting medicines (if explicitly listed): Warfarin; Acenocoumarol.
Mechanistic basis of interactions (only if stated in label): Pharmacodynamic interaction (enhanced anticoagulant effect); Pharmacokinetic interaction (enhanced gastrointestinal absorption of a co-administered drug); Metabolic interaction (documented lack of significant inhibition of major CYP P450 enzymes).
Timing-based interaction rules (if applicable): No mandatory timing separation rules are explicitly documented.
Population-specific interaction notes (if applicable): Required monitoring for patients with diabetes taking hypoglycaemic agents.
Interaction-related restrictions: Mandatory monitoring of coagulation parameters (INR) when initiating or discontinuing Recosine in patients on Coumarinic Anticoagulants.

Interaction classifications (high-level)

Classification Description
Interaction severity classification (as defined in official documents): Clinically significant interaction requiring close monitoring (Oral Vitamin K Antagonists); Interaction with low clinical relevance (Tetracyclines); Low potential for metabolic interaction (CYP enzymes).
Interaction-context constraints (as defined in official documents): Procedural constraint for coagulation monitoring; Monitoring constraint for blood glucose levels.

Resulting interaction structure

Official interaction statements:

  • The co-administration of Recosine with Coumarinic Anticoagulants (such as Warfarin) has been formally associated with an enhanced anticoagulant effect, evidenced by increases in the International Normalized Ratio (INR).
  • Patients on these anticoagulants must have their coagulation parameters closely monitored when Recosine is started or stopped.
  • Recosine may enhance the gastrointestinal absorption and subsequently increase the serum concentrations of co-administered Tetracycline-class antibiotics (pharmacokinetic interaction).
  • Regulatory documentation indicates Recosine has a low potential for metabolic interaction because it does not significantly inhibit or induce major Cytochrome P450 enzymes (CYP1A2, CYP3A4, etc.).
  • A population-specific caution requires close monitoring of blood sugar levels for patients with diabetes who are taking Hypoglycaemic Agents.

Connection to the overall interaction profile (2–4 sentences):

Official regulatory documents define the product's primary interaction structure around a clinically significant pharmacodynamic interaction with Oral Vitamin K Antagonists, which results in a mandatory monitoring requirement. The profile is further structured by a low potential for metabolic interaction and a specific pharmacokinetic interaction affecting Tetracycline exposure. The remaining constraint is a required procedure for blood glucose level monitoring in diabetic patients co-administering anti-diabetic agents.

Mechanism of Action

Cation Exchange in the Gastrointestinal Tract

Recosine is an ion-exchange polymer resin that is not absorbed into the systemic circulation from the gastrointestinal tract. Its mechanism of action is limited to the lumen of the large intestine. The resin engages a chemical exchange process, specifically replacing its own bound counter-ion for specific cations present in the intestinal contents, primarily potassium ions. This interaction is highly selective and physical, preventing the target cation from crossing the mucosal barrier and entering the bloodstream.

Modification of Enteric Cation Levels

This exchange process facilitates the sequestration of the targeted cations, binding them securely within the non-absorbable resin matrix. The resulting effect is a reduction of the free cation concentration in the intestinal lumen, which alters the concentration gradient across the intestinal wall. The sequestered cation, bound to the Recosine resin, is subsequently eliminated from the body via excretion in the feces, modifying the overall homeostatic pathways governing systemic electrolyte distribution.

Dosage and Administration Information

Official Administration Guidelines

Recosine is administered exclusively via the oral route, using a standardized regimen. The typical daily dose is fixed to ensure consistent intake for long-term management of chronic joint conditions.

Instruction Scope Instruction Details
Route of Administration Oral route only (tablets, capsules, or powder for solution).
Standard Adult Dosing 1500 mg (Glucosamine sulfate) once daily. This is also the maximum recommended daily dose.
Frequency and Timing Once daily (QD), typically administered in a single dose. May be taken with or without food.
Preparation Powder forms must be dissolved entirely in water before consumption. Tablets/capsules are generally swallowed whole.

Use Patterns and Population Rules

The treatment protocol is established for chronic administration, not acute painful episodes. Specific boundaries for use are defined across different patient groups:

Population Group Administration Rule
Pediatric Population Not recommended for use in persons under 18 years due to insufficient data.
Treatment Duration Continuous use is required; re-evaluation of treatment continuation is advised if no symptomatic relief occurs after 2–3 months of sustained administration.

These instructions establish a protocol focused on sustained, consistent administration within defined patient boundaries.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Recosine

Evidence for Symptomatic Relief in Knee Osteoarthritis

Recosine was studied for outcomes related to physical discomfort in patients with knee osteoarthritis. This research has largely relied on Randomized Controlled Trials (RCTs), where people are randomly assigned to receive either Recosine or an inactive placebo. Studies are typically applied in research contexts involving fluctuating or unstable symptoms, and researchers was evaluated in research exploring how symptoms change over time, monitoring factors such as joint pain and stiffness, as well as changes in outcomes reflecting daily functioning or activity level.

In this research, findings were mixed. Many studies using specific, patented forms of Glucosamine Sulfate reported patterns where the measured changes in patient symptoms differed from the patterns observed in the placebo groups. However, other independent and high-quality trials, particularly those that were observed in patients using other formulations, such as Glucosamine Hydrochloride, reported measurements where the change in symptoms was associated with patterns similar to placebo.

The research provides insight into short-term changes only for specific types of Glucosamine, while the data for certain groups remain insufficient for other types. The overall evidence contributes to the broader evidence landscape but certainty remains low when considering all Glucosamine products together, especially since many studies excluded patients with severe osteoarthritis.

Studies on Potential Joint Structure Changes

Long-term research has also studies monitored outcomes reflecting daily functioning or activity level and the physical structure of the joint. These long-duration trials, often lasting two to three years, studies monitored patients with knee OA for slow, structural changes. Researchers research examined structural changes by monitoring the minimum joint space width through X-rays.

Studies focusing on a specific Glucosamine Sulfate product reported patterns where the measured rate of cartilage loss (joint space narrowing) in the Glucosamine group was observed in some studies to follow a different pattern compared to the placebo group. Additionally, some long-term observational settings evaluating daily-life functioning data show patterns related to participants consistently using Recosine and the frequency of total knee replacement surgery. This research provides context but not individual predictions.

However, the change in joint space width that was associated with Recosine is typically small, and its clinical relevance—meaning, how much that difference impacts a patient's daily comfort and function—is not fully established. Furthermore, this long-term structural evidence is derived almost entirely from trials using one specific formulation, meaning the data for certain groups remain insufficient to generalize to all types of Recosine available on the market.

Frequently Asked Questions (FAQ)

Common questions about Recosine (FAQ)


Q: How quickly can I expect Recosine to start working?

Official documents state that the relief of symptoms, such as pain, may take several weeks to be noticeable. Because Recosine is used for long-term management, it is noted that immediate relief is not typically observed. If there is no symptomatic relief after two to three months, re-evaluation of the continuation of use is advised.


Q: Does Recosine interact with common supplements like vitamins or herbal remedies?

Regulatory information primarily focuses on potential interactions with prescription medicines. Official product documents indicate a low potential for metabolic interaction, which suggests that the potential for metabolic interaction with many supplements may be low, but only medicinal products are explicitly addressed in the documents.


Q: Why do some people need to take Recosine longer than others?

Recosine is intended for chronic, continuous use, and the treatment duration is established based on the required continuous use and the need for symptomatic re-evaluation. Official guidelines advise that the need for continued treatment should be re-evaluated if a patient experiences no symptomatic relief after two to three months of consistent use.


Q: What if I take too much Recosine by accident?

In the event of an accidental overdose, the official guidance is to discontinue taking Recosine. No specific antidote is listed in the product information, and treatment involves the adoption of symptomatic and standard supportive measures, as described in official information.


Q: Does Recosine treat the cause or just the symptoms?

Recosine is officially indicated for the relief of symptoms related to mild to moderate osteoarthritis. Its active component is a fundamental structural component of cartilage. Official information states Glucosamine is indicated for symptom relief, and it is also described as a key precursor for the synthesis of connective tissue elements.


Q: Does Recosine build up in your system over time?

The active component, Glucosamine, is absorbed and persists in the circulation for an extended period, which supports its once-daily dosing. The active substance is utilized by the body through natural metabolic pathways, either by being incorporated into structural compounds or by degradation, similar to endogenous substances.


Q: What should I do if I miss a dose of Recosine?

If a dose is missed, official patient guidance recommends skipping the missed dose if it is nearly time for the next scheduled dose. Official guidance states that a double dose should not be taken to compensate for a single missed dose.


Q: Is it safe to drink alcohol while taking Recosine?

Specific drug-alcohol interactions are not documented in the official regulatory product information. However, it is noted that alcohol consumption may potentially intensify common central nervous system side effects of the medicine, such as sleepiness or dizziness.


Q: Are there any foods or supplements that interact with Recosine?

Recosine may be taken with or without food. Official documents list no general dietary restrictions regarding food or non-medicinal supplements, though drug-drug interactions are documented.


Q: Is it normal to feel tired or drowsy when starting Recosine?

Tiredness (fatigue) is listed in official documents as a common adverse reaction. Post-marketing reports have also included sleepiness (somnolence) as a potential undesirable effect that may be experienced when using this product.


Q: Does Recosine affect your ability to drive or operate machinery?

Because Recosine has been reported to cause side effects such as sleepiness, headache, or dizziness, regulatory authorities advise caution. Official product information advises that individuals should exercise caution and not drive or operate machinery until they are certain the medicine does not interfere with their abilities.


Q: How is Recosine cleared from the body?

The active substance is known to be utilized by the body through incorporation into structural compounds or by degradation, following the body’s natural metabolic pathways. It is noted that the product is unlikely to be eliminated via the cytochrome enzyme system in the liver, which is the main metabolic pathway for many other medicines.


Q: What happens if I stop taking Recosine suddenly?

Recosine is used for chronic management, and the documentation does not include specific warnings regarding abrupt cessation or withdrawal symptoms. The product is designed for long-term use, and the need for continued use is subject to periodic re-evaluation.


Q: How does Recosine compare to placebo in clinical trials?

Research findings are available for specific Glucosamine formulations. Studies showed symptom changes that differed from placebo in some trials, while other high-quality studies reported results similar to placebo. Official documents note that the clinical relevance of the difference in joint space width is not fully established, and certainty remains low when considering all Glucosamine products together.


Q: Does Recosine need to be taken with food?

According to the official administration instructions, Recosine tablets or capsules can generally be taken with or without food.


Q: Does Recosine have an antidote?

Official guidance regarding overdose does not list a specific antidote for Recosine. In cases where too much is taken, treatment involves stopping the product and the adoption of symptomatic and standard supportive measures, as described in official information.


Q: Can Recosine cause a rash or allergic reaction?

Yes, regulatory documents list skin rash, itching, and redness as uncommon side effects. There is also a documented potential for rare, severe hypersensitivity reactions (allergic reactions). Use is formally prohibited for individuals with a known shellfish allergy.


Q: How long does the effect of one dose of Recosine typically last?

Pharmacokinetic studies have indicated that the Glucosamine active component has an elimination half-life of approximately 15 hours. This finding is consistent with and supports the recommended once-daily dosage schedule described in the official instructions.


Q: Are there any dietary restrictions while on Recosine?

There are no general food restrictions. However, the product is contraindicated for people with a known shellfish allergy if the Glucosamine is sourced from crustaceans. Additionally, some formulations are contraindicated for patients with specific hereditary sugar intolerances.


Q: Does Recosine affect your cholesterol levels?

Official safety documents include a caution stating that monitoring of blood lipid levels, which include cholesterol, may be required for patients with known cardiovascular risk factors. This is because elevated cholesterol (hypercholesterolemia) has been observed in a few patients treated with Glucosamine.

How should Recosine be stored and disposed of?

Official Storage and Disposal Requirements

Recosine (Glucosamine) must be stored under specific conditions to ensure product stability, as mandated by regulatory documents.

Storage Conditions

The product must be stored at a temperature not exceeding 30 C (86 F). It is required to keep the medicine in its original outer carton to maintain protection and integrity. For child safety, the product must be kept out of the sight and reach of children at all times.

Disposal Instructions

Unused or expired Recosine must be disposed of according to local requirements for pharmaceutical waste. The official labeling specifies that the medicine must not be thrown away in household waste or released into the wastewater system to prevent environmental contamination. Consult a local pharmacy for correct disposal procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Recosine found in:

A-Z Index: